EUCTR2020-005028-13-DK进行中（未招募）1 期
A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2a related Genetic Alterations - Belzutifan/MK-6482 to treat PPGL, pNET, VHL dis,wt GIST or Adv Solid Tumors with HIF-2a alterations
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 337
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Cohort A1: PPGL
- •1. Has documented histopathological diagnosis (local report) of pheochromocytoma or paraganglioma
- •2. Has locally advanced or metastatic disease that is not amenable to surgery or curative intent treatment
- •3. Adequately controlled blood pressure defined as blood pressure =150/90 mm Hg (=135/85 mm Hg for adolescents) and with no change in antihypertensive medications (for participants with concomitant hypertension) for at least 2 weeks prior to start of study treatment
- •Cohort A2: pNET
- •4. Has documented histopathological or cytopathological diagnosis (local report) of well-differentiated, low or intermediate grade (G1 or G2 pNET per 2017 WHO classification and grading) pNET
- •5. Has locally advanced disease or metastatic disease that is:
- •a. Not amenable for surgery, radiation, locoregional therapies or combination modality of such treatments with curative intent
- •b. Experienced disease progression on or after at least 1 line of prior systemic therapy that includes an approved targeted agent such as everolimus (mTOR inhibitor) or sunitinib (antiVEGF targeted agent). Participants who have received >3 prior systemic therapies will be capped to =20% of the cohort
- •6. Has disease progression within the past 12 months from Screening (Cohorts A1, A2 and PPGL/pNET participants from Cohort D)
- •7. Has measurable disease per RECIST v1.1 by CT or MRI as assessed by local site investigator/radiology assessment and verified by BICR.
- •a. Irradiated lesions or lesions treated with locoregional therapies should not be used as target lesions unless they clearly demonstrate growth since completion of radiation
- •b. Metastatic lesions situated in the brain are not considered measurable and should be considered nontarget lesions. This criterion does not apply to Cohort B1 participants.
- •c. Only lesions of the primary indication for the cohort may be evaluated for measurability; other neoplastic lesions will be documented by the investigator and this information provided to the independent reviewers to ensure that such lesions are not included in the RECIST assessment
- •8. Is male or female, 12 years of age inclusive (=40 kg for adolescents [12-17 years of age]), at the time of providing the informed consent. Only adult participants (=18 years of age) are eligible to participate for Cohort B1.
- •9. Male participants are eligible to participate if they agree to the following during the intervention period and for at least 7 days after the last dose of study intervention:
- •Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent
- •Must agree to use contraception unless confirmed to be azoospermic (vasectomized or secondary to medical cause) as detailed below:
- •- Agree to use a male condom plus partner use of an additional contraceptive method when having penile-vaginal intercourse with a WOCBP who is not currently pregnant
- •Contraceptive use by men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
- •10. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
- •Is not a WOCBP
- •Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of <1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyl
排除标准
- •1. Is unable to swallow orally administered medication or has a disorder that might affect the absorption of belzutifan
- •2. Has a history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 years with the following exceptions:
- •a) Participants with history of VHL disease will be permitted provided concurrent lesions (other than the tumor type being assessed such as PPGL for Cohort A1 and pNET for Cohort A2) are localized without immediate need for intervention. Cohort D participants with VHL disease will not be eligible
- •b) Prior history of surgical resection(s) for concurrent localized VHL disease-associated tumors is allowed provided there is no history of metastatic disease from concurrent tumors; history of systemic therapy for concurrent tumors will be exclusionary
- •c) Participants with history of other genetic syndromes will be allowed provided concurrent tumors (outside of the organ affected in Cohort A1 and Cohort A2, C and D respectively) are localized and do not require immediate intervention; history of metastatic disease in concurrent tumors or history of systemic therapy for concurrent tumors will be exclusionary.
- •d. Refer to exclusion criterion protocol section 5.2 for Cohort B1 participants
- •3. Has known CNS metastases and/or carcinomatous meningitis
- •4. Has any of the following:
- •A pulse oximeter reading <92% at rest, or
- •Requires intermittent supplemental oxygen, or
- •Requires chronic supplemental oxygen
- •5. Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction, or CABG or PTCA =6 months from Day 1 of study drug administration, or New York Heart Association Class III or IV congestive heart failure. Concurrent uncontrolled hypertension defined as BP >150/90 mm Hg despite optimal antihypertensive medications within 2 weeks prior to the first dose of study treatment
- •6. Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study
- •7. Has had major surgery =4 weeks prior to first dose of study intervention
- •8. Has received prior treatment (except somatostatin analogs for pNET participants) with chemotherapy, targeted therapy, biologics or other inv. therapy within the past 4 weeks of first dose of study intervention.
- •9. Has received prior locoregional therapies or radiation within the past 4 weeks of first dose of study intervention.
- •10. Has received prior treatment with PRRT/radionuclide therapy or other radiopharmaceutical therapy within the past 12 weeks from screening for participants with pNET
- •11. Has received MIBG therapy or other radiopharmaceutical therapy within the past 12 weeks from screening for participants with PPGL
- •12. Has received prior treatment with any HIF-2a inhibitor
- •13. Has a known hypersensitivity to the study treatment and/or any of its excipients
- •14. Has toxicities from prior locoregional or systemic or any other therapies that is not recovered to CTCAE =Grade 1
- •15. Has received colony-stimulating factors =28 days prior to the first dose of study intervention
- •16. Is currently receiving strong inhibitors of CYP3A4 that cannot be discontinued for the duration of the study
- •17. Is currently receiving either strong or moderate inducers of CYP3A4 that cannot be discontinued for the duration of the study
- •18. Is currently enrolled in and receiving study therapy, was enrolled in a study of an inv. agent and received study therapy or used an in
研究者
相似试验
进行中（未招募）
1 期
A Phase 2 Study to Evaluate the Efficacy and Safety of LY3462817 in Participants with Moderately to Severely Active Rheumatoid ArthritisEUCTR2020-002673-10-HUEli Lilly and Company80
进行中（未招募）
1 期
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)Extensive-Stage Small Cell Lung CancerEUCTR2020-005649-17-ATMerck Sharp & Dohme LCC, a subsidiary of Merck & Co., Inc.120
进行中（未招募）
1 期
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic MalignanciesMedDRA version: 20.0Level: PTClassification code 10003899Term: B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: HLTClassification code 10026798Term: Mantle cell lymphomasSystem Organ Class: 100000004851MedDRA version: 21.1Level: LLTClassification code 10054693Term: Von Waldenstrom macroglobulinemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10076596Term: Marginal zone lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-002324-36-CZMerck Sharp & Dohme LLC450
招募中
1 期
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic MalignanciesFollicular lymphomaCTIS2023-504931-42-00Merck Sharp & Dohme LLC502
进行中（未招募）
1 期
A Phase 2 Study of belzutifan (MK-6482) Monotherapy in Participants with Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET)EUCTR2020-005028-13-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.140